InspireMD, Inc. announced on July 31, 2025, that it raised approximately $58 million in combined gross proceeds through an equity private placement (PIPE) financing and the exercise of warrants. This significant capital infusion was triggered by the FDA's Premarket Application (PMA) approval of the CGuard Prime carotid stent system.
The PIPE financing generated $40.1 million in gross proceeds, led by current investors OrbiMed and Marshall Wace, with participation from new and existing investors, including InspireMD board members. The company agreed to issue 16,556,184 shares of common stock and pre-funded warrants at a purchase price of $2.42 per share.
Additionally, the exercise of warrants, which was the second tranche of a milestone-based financing announced in May 2023, generated $17.9 million in gross proceeds. CEO Marvin Slosman stated that these transactions fortified the shareholder base, broadened investor reach, and significantly strengthened the balance sheet, providing the ability to rapidly expand commercial growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.